Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Huadao (Shanghai) Biomedical Co., Ltd. engages in the development of biomedical technology. It also engages in the research and development of pharmaceutical products and provides technology consulting and transfer services. The company was founded by Xue Jun Yu on September 30, 2017 and is headquartered in Shanghai, China.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Shanghai Maishi Biotechnology Co., Ltd., established on 2018-05-04, Business scope includes biotechnology,Technology development in the field of medical technology,technology transfer,technical consulting,Technical Services,Chemical products and raw materials(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),Research and development of biological reagents for non-clinical diagnosis,Sales,Engaged in the import and export of goods and technology.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.]

Eutilex Co., Ltd. develops anti-tumor T cell therapy and antibody therapeutics based on proprietary immunotherapy technology. It offers T Cell Therapy, Antibody, CAR-T Cell Therapy. The company was founded by Kwon Byoung S on February 27, 2015 and is headquartered in Seoul, South Korea.

Shenzhen Chuangshi Biomedical Co., Ltd., established on 2019-08-07, Business scope includes general business items:Biotechnology Extension Services;Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:pharmaceutical production;sales of medicines.

Dashi Pharmaceutical (Guangdong) Co., Ltd., established on 2017-08-22, Business scope includes biotechnology extension services;Sales:laboratory equipment,Instrumentation;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)(The above business scope involves the import and export of goods,Technology Import and Export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada

Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA.

Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland.

Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA.

Baifan Biotechnology (Shanghai) Co., Ltd., established on 2016-10-25, Business scope includes general items:engaged in biotechnology,Technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer;Production of monoclonal antibody stock solutions and preparations,Sales;Import and export;Technology Import and Export;Specialty Chemicals Sales(Free of Hazardous Chemicals);Instrument sales;Sales of bio-based materials.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

AroCell AB is a in vitro diagnostics company, which engages in the monitoring of hematological malignancies, breast cancer, and other solid tumors. Its products include AroCell TK 210 ELISA, which was designed for simple, robust, and scalable measurement of Thymidine Kinase 1 (TK1) in blood samples. The company was founded by Karl Axel Staffan Eriksson, Arne Ferstad, Qi Min He, Per Nils Jesper Matsson, Sven Skog, and Bernhard Tribukait in 2003 and is headquartered in Stockholm, Sweden.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.